绿叶制药一类创新药若欣林新适应症广泛性焦虑障碍在华上市申请获受理

美股速递
Jan 08

绿叶制药宣布,其一类创新药若欣林(Ruoxinlin)针对广泛性焦虑障碍(GAD)的新适应症上市申请已获中国药品监管部门受理。此次受理标志着该药物在拓展治疗领域方面取得重要进展,有望为更多焦虑症患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10